Stentys: First Quarter Revenues Up 18% From 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

STENTYS (FR0010949404 – STNT), a medical technology company commercializing the world’s first and only Self-Apposing® stent to treat Acute Myocardial Infarction (AMI), today announces its revenues for the first quarter ending March 31, 2014.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC